These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 21838757)

  • 1. Dynamic monitoring of beating periodicity of stem cell-derived cardiomyocytes as a predictive tool for preclinical safety assessment.
    Abassi YA; Xi B; Li N; Ouyang W; Seiler A; Watzele M; Kettenhofen R; Bohlen H; Ehlich A; Kolossov E; Wang X; Xu X
    Br J Pharmacol; 2012 Mar; 165(5):1424-41. PubMed ID: 21838757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multi-parametric assessment of cardiomyocyte excitation-contraction coupling using impedance and field potential recording: A tool for cardiac safety assessment.
    Zhang X; Guo L; Zeng H; White SL; Furniss M; Balasubramanian B; Lis E; Lagrutta A; Sannajust F; Zhao LL; Xi B; Wang X; Davis M; Abassi YA
    J Pharmacol Toxicol Methods; 2016; 81():201-16. PubMed ID: 27282640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety pharmacology studies using EFP and impedance.
    Obergrussberger A; Juhasz K; Thomas U; Stölzle-Feix S; Becker N; Dörr L; Beckler M; Bot C; George M; Fertig N
    J Pharmacol Toxicol Methods; 2016; 81():223-32. PubMed ID: 27084108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of human stem cell-derived cardiomyocytes in safety pharmacology requires caution beyond hERG.
    Jonsson MK; Vos MA; Mirams GR; Duker G; Sartipy P; de Boer TP; van Veen TA
    J Mol Cell Cardiol; 2012 May; 52(5):998-1008. PubMed ID: 22353256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (I(Kr)) channel.
    Davie C; Pierre-Valentin J; Pollard C; Standen N; Mitcheson J; Alexander P; Thong B
    J Cardiovasc Electrophysiol; 2004 Nov; 15(11):1302-9. PubMed ID: 15574182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A place for high-throughput electrophysiology in cardiac safety: screening hERG cell lines and novel compounds with the ion works HTTM system.
    Guthrie H; Livingston FS; Gubler U; Garippa R
    J Biomol Screen; 2005 Dec; 10(8):832-40. PubMed ID: 16234341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of cellular impedance measures of cardiomyocyte cultures for drug screening applications.
    Peters MF; Scott CW; Ochalski R; Dragan YP
    Assay Drug Dev Technol; 2012 Dec; 10(6):525-32. PubMed ID: 22574652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Electrophysiological evaluation of pentamidine and 17-AAG in human stem cell-derived cardiomyocytes for safety assessment.
    Asahi Y; Nomura F; Abe Y; Doi M; Sakakura T; Takasuna K; Yasuda K
    Eur J Pharmacol; 2019 Jan; 842():221-230. PubMed ID: 30391349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional Impact of BeKm-1, a High-Affinity hERG Blocker, on Cardiomyocytes Derived from Human-Induced Pluripotent Stem Cells.
    De Waard S; Montnach J; Ribeiro B; Nicolas S; Forest V; Charpentier F; Mangoni ME; Gaborit N; Ronjat M; Loussouarn G; Lemarchand P; De Waard M
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32998413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro electrophysiological drug testing using human embryonic stem cell derived cardiomyocytes.
    Caspi O; Itzhaki I; Kehat I; Gepstein A; Arbel G; Huber I; Satin J; Gepstein L
    Stem Cells Dev; 2009; 18(1):161-72. PubMed ID: 18510453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. hERG-related drug toxicity and models for predicting hERG liability and QT prolongation.
    Raschi E; Ceccarini L; De Ponti F; Recanatini M
    Expert Opin Drug Metab Toxicol; 2009 Sep; 5(9):1005-21. PubMed ID: 19572824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human embryonic stem cell derived cardiac myocytes detect hERG-mediated repolarization effects, but not Nav1.5 induced depolarization delay.
    Qu Y; Gao B; Fang M; Vargas HM
    J Pharmacol Toxicol Methods; 2013; 68(1):74-81. PubMed ID: 23518063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional cardiotoxicity profiling and screening using the xCELLigence RTCA Cardio System.
    Xi B; Wang T; Li N; Ouyang W; Zhang W; Wu J; Xu X; Wang X; Abassi YA
    J Lab Autom; 2011 Dec; 16(6):415-21. PubMed ID: 22093298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of FDSS/μCell imaging platform for preclinical cardiac electrophysiology safety screening of compounds in human induced pluripotent stem cell-derived cardiomyocytes.
    Zeng H; Roman MI; Lis E; Lagrutta A; Sannajust F
    J Pharmacol Toxicol Methods; 2016; 81():217-22. PubMed ID: 27222351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.
    Redfern WS; Carlsson L; Davis AS; Lynch WG; MacKenzie I; Palethorpe S; Siegl PK; Strang I; Sullivan AT; Wallis R; Camm AJ; Hammond TG
    Cardiovasc Res; 2003 Apr; 58(1):32-45. PubMed ID: 12667944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does terfenadine-induced ventricular tachycardia/fibrillation directly relate to its QT prolongation and Torsades de Pointes?
    Lu HR; Hermans AN; Gallacher DJ
    Br J Pharmacol; 2012 Jun; 166(4):1490-502. PubMed ID: 22300168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human stem cell models for predictive cardiac safety pharmacology.
    Braam SR; Mummery CL
    Stem Cell Res; 2010 May; 4(3):155-6. PubMed ID: 20493455
    [No Abstract]   [Full Text] [Related]  

  • 18. High-performance beating pattern function of human induced pluripotent stem cell-derived cardiomyocyte-based biosensors for hERG inhibition recognition.
    Hu N; Wang T; Wang Q; Zhou J; Zou L; Su K; Wu J; Wang P
    Biosens Bioelectron; 2015 May; 67():146-53. PubMed ID: 25153933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the IKr blockers moxifloxacin, dofetilide and E-4031 in five screening models of pro-arrhythmia reveals lack of specificity of isolated cardiomyocytes.
    Nalos L; Varkevisser R; Jonsson MK; Houtman MJ; Beekman JD; van der Nagel R; Thomsen MB; Duker G; Sartipy P; de Boer TP; Peschar M; Rook MB; van Veen TA; van der Heyden MA; Vos MA
    Br J Pharmacol; 2012 Jan; 165(2):467-78. PubMed ID: 21718297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human ether-a-go-go-related (HERG) gene and ATP-sensitive potassium channels as targets for adverse drug effects.
    Zünkler BJ
    Pharmacol Ther; 2006 Oct; 112(1):12-37. PubMed ID: 16647758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.